Bicara Therapeutics Inc. Common Stock (BCAX) Stock Price

BCAXStock
$24.58+99.16%52W
Market Cap$1.63B
P/E
PEG Ratio
Div yield
Beta0.85

BCAX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)51.49%
Price vs S&P 500 (4W)-15.33%
VGM Score69.32

BCAX Earnings Surprise History

Q2 25-0.50est. -0.54
Q3 25-0.67est. -0.53
Q4 25-0.68est. -0.65
Q1 26-0.93est. -0.65
Q2 26-0.82est. -0.83

BCAX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BCAXBicara Therapeutics Inc. Common Stock
B$24.58
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed monoclonal antibody with a TGF-beta binding domain, targeting two clinically validated oncology pathways.